Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL3707643 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL16312 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2672138 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL1598 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL6431587 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7191483 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7626175 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL7189499 | 0.98 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL2916993 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 | |
| Sibutramine SCHEMBL4594859 | 0.97 | CYP3A4 (0.97) | SLC6A3SLC6A4SLC6A2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 33527 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-0282206-B1 | ARYLCYCLOBUTYLALKYLAMINE-DERIVATIVE FOR THE TREATMENT OF PARKINSON'S DISEASE | The Boots Company PLC (GB) | 1990-11-07 | — | — | EP | claimed |
| EP-0230742-B1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1990-09-26 | — | — | EP | claimed |
| US-4939175-A | Cognition activators; alzheimer*s disease | THE BOOTS CO. PLC (GB) | 1990-07-03 | — | — | US | claimed |
| EP-0339280-A2 | Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders | The Boots Company PLC (GB) | 1989-11-02 | — | — | EP | claimed |
| EP-0303677-A1 | ARYLCYCLOBUTYL DERIVATIVES FOR TREATMENT OF PARKINSON'S DISEASE | The Boots Company PLC (GB) | 1989-02-22 | — | — | EP | claimed |
| EP-0282206-A1 | Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease | The Boots Company PLC (GB) | 1988-09-14 | — | — | EP | claimed |
| WO-1988006444-A1 | ARYLCYCLOBUTYL DERIVATIVES FOR TREATMENT OF PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1988-09-07 | — | — | WO | claimed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | claimed |
| EP-0230742-A1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1987-08-05 | — | — | EP | claimed |
| US-4522828-A | CYCLOBUTYLALKYLAMINE COMPOUNDS, ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1985-06-11 | — | — | US | claimed |